ERBB2 and neoplasm: Besides PD-L1 CPS, Her2 overexpression, and tumor mutation burden, multi-omics analysis also revealed several biomarkers predictive of pathological response, including RREB1 and SSPO mutations, immune-related signatures, and a peripheral T cell expansion score (52).